DFTX
The table below shows Definium Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $41.48M | $30.98M | $29.81M | $23.36M | $17.19M | $14.64M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $17.74M |
| $14.69M |
| $11.09M |
| $8.80M |
| $7.60M |
| $9.81M |
| Operating income | -$59.22M | -$45.67M | -$40.90M | -$32.16M | -$24.79M | -$24.46M |
| Income tax | - | - | - | - | - | - |
| Net income | -$77.10M | -$67.27M | -$42.74M | -$23.35M | -$13.68M | -$5.85M |
| EPS (diluted) | -$0.71 | -$0.78 | -$0.50 | -$0.35 | -$0.27 | -$0.26 |